Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo
| Autor: | Nicholas M. Beskid, Andrew B. Adams, Julia E. Babensee, Ying Dong, Andrés J. García, Aline M. Thomas |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
endocrine system diseases Physiology Clinical Biochemistry Bone Marrow Cells T-Lymphocytes Regulatory Article Mice 03 medical and health sciences 0302 clinical medicine Immune system In vivo Precursor cell Immune Tolerance medicine Animals Humans CD86 Chemistry Cell Differentiation Dendritic Cells Cell Biology Dendritic cell In vitro Interleukin-10 Cell biology Interleukin 10 Glucose 030104 developmental biology medicine.anatomical_structure Hyperglycemia 030220 oncology & carcinogenesis B7-2 Antigen Bone marrow |
| Zdroj: | J Cell Physiol |
| ISSN: | 1097-4652 0021-9541 |
| DOI: | 10.1002/jcp.29380 |
| Popis: | Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin (STZ)-induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, of which tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel-based delivery of the anti-inflammatory molecule interleukin-10 (IL-10) was shown to partially inhibit these effects in vivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text